• A novel intelligent biosensing platform integrates quantum dots luminescence, microfluidic biochip, and machine vision algorithm for point-of-care CEA protein diagnostics.
• The platform achieves an outstanding detection limit of approximately 0.021 ng mL−1 for CEA, surpassing commercial lateral flow assay strips.
• Machine vision algorithm enhances portability and integration, expanding the potential of point-of-care biosensing applications.
• Validation with human-sourced artificial saliva samples demonstrates superior detection capabilities compared to commercial rapid test strips.